Sax Wealth Advisors LLC Has $1.32 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Sax Wealth Advisors LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 97.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,354 shares of the company’s stock after purchasing an additional 1,163 shares during the quarter. Sax Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $1,323,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Elyxium Wealth LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $3,666,459,000. J. Stern & Co. LLP grew its stake in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after acquiring an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares during the period. Wellington Management Group LLP increased its position in IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after acquiring an additional 592,834 shares during the period. Finally, Norges Bank acquired a new position in IDEXX Laboratories during the 4th quarter valued at $332,265,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IDXX. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. UBS Group boosted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $756.00.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $586.67 on Monday. The firm has a market capitalization of $46.22 billion, a PE ratio of 41.26, a price-to-earnings-growth ratio of 3.18 and a beta of 1.54. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The firm has a 50-day moving average price of $559.73 and a 200 day moving average price of $584.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the previous year, the business earned $3.50 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 14.82 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.